Takeda Clinical Trial Pipeline — 104 Active Studies

Takeda pipeline at a glance (March 2026)

About the Takeda clinical program

Takeda's pipeline spans oncology, gastroenterology, rare disease, and plasma-derived therapies. Their oncology franchise includes Alunbrig (brigatinib) for ALK-positive NSCLC — competitive with Lorbrena in the post-crizotinib setting — and Ninlaro (ixazomib), the first oral proteasome inhibitor for multiple myeloma. In gastroenterology, Entyvio (vedolizumab) for IBD has one of the most active label expansion programs in the specialty. Their rare disease portfolio (alpha-1 antitrypsin deficiency, Fabry disease, hereditary angioedema) continues generating Phase 3 trials. Takeda is also advancing TAK-279 (zasocitinib), a TYK2 inhibitor, as a potential competitor to Bristol Myers Squibb's deucravacitinib in psoriasis and PsA.

Key therapeutic areas

• Oncology (NSCLC, multiple myeloma, lymphoma)
• Gastroenterology / IBD
• Rare / plasma-derived
• Neuroscience
• Immunology (TYK2, IL)

Key pipeline programs

• Alunbrig (brigatinib) — ALK inhibitor, NSCLC
• Ninlaro (ixazomib) — oral proteasome inhibitor, myeloma
• Entyvio (vedolizumab) — α4β7 integrin, IBD/Crohn's/UC
• TAK-279 (zasocitinib) — TYK2 inhibitor, psoriasis/PsA
• Fruquintinib — VEGFR 1/2/3 inhibitor, CRC (via Zymeworks)
• TAK-981 — SUMO pathway inhibitor, lymphoma

Top Takeda trial indications

Condition / Indication	Trials
["Hereditary Angioedema (HAE)"]	7
["Crohn's Disease"]	4
["Colorectal Cancer"]	4
["Ulcerative Colitis", "Crohn's Disease"]	3
["Psoriatic Arthritis"]	3
["Multiple Myeloma"]	3
["Thrombotic Thrombocytopenic Purpura (TTP)"]	3
["Dengue Fever"]	3

Why monitor Takeda's clinical trial activity

Takeda's TYK2 inhibitor zasocitinib is the most significant competitive threat to BMS's deucravacitinib (Sotyktu) in the psoriasis/PsA space. Any dermatology-focused company should monitor Takeda's Phase 3 program. In GI, new Entyvio combinations and IBD programs are closely watched by companies developing competing gut-selective biologics.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Takeda's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.

How DataLookout tracks Takeda trials

• Sponsor normalization: Takeda may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.

Frequently asked questions

What is Takeda's focus in current clinical trials?

Takeda's most active trial areas are oncology (ALK-positive NSCLC, multiple myeloma, lymphoma), gastroenterology/IBD (Entyvio combinations and next-generation programs), and immunology (TYK2 inhibitor zasocitinib in psoriasis, psoriatic arthritis). Their rare disease and plasma-derived pipeline also generates consistent Phase 3 activity.

How many Takeda trials are currently recruiting?

Based on current ClinicalTrials.gov data, 49 Takeda-sponsored trials are actively recruiting patients globally.

Can I filter Takeda trials by therapeutic area?

Yes. DataLookout watchlists support keyword filtering by condition, mechanism, or drug name. You can create a Takeda oncology watchlist (filtering for cancer indications) separately from a Takeda GI watchlist (filtering for Crohn's, UC, IBD), each delivering a targeted daily digest.